Want to see IN:HIKAL full AI Analyst Report?
HIKAL Stock Chart & Stats
₹217.20
₹4.58(2.11%)
At close: 4:00 PM EDT
₹217.20
₹4.58(2.11%)
Day’s Range― - ―
52-Week Range₹145.95 - ₹282.70
Previous CloseN/A
Volume197.35K
Average Volume (3M)34.88K
Market Cap
₹26.23B
Enterprise Value₹34.81K
Total Cash (Recent Filing)₹138.00M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)-2.74
Shares Outstanding123,300,750
10 Day Avg. Volume44,586
30 Day Avg. Volume34,881
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.51
Price to Sales (P/S)1.06
P/FCF Ratio20.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)5.9
Revenue Forecast (FY)₹18.64B
Bulls Say, Bears Say
Bulls Say
Specialty CDMO Business ModelHikal's specialty-chemicals CDMO model and process-chemistry capabilities create durable customer lock-in. Multi-step synthesis, scale-up and regulated manufacturing establish technical barriers and enable multi-year supply relationships, supporting recurring B2B revenues and steady order pipelines.
Manageable LeverageDeclining debt and debt at ~25% of assets improves financial flexibility. A sizable equity base plus lower leverage supports capital allocation for operations or growth, and provides a cushion against cyclical shocks in pharma/agro sectors over the next several months to years.
Cash Generation ResiliencePositive operating and free cash flow even during a net loss year shows the business can convert revenues into cash. This supports working-capital needs, funds maintenance capex and reduces immediate refinancing risk, underpinning operations while management addresses profitability.
Bears Say
Profitability DeteriorationA swing to net losses undermines retained earnings and reduces internal funds for R&D or capacity additions. Persisting losses risk eroding equity, constrain strategic investments and could force cost cuts or higher borrowing, weakening long-term competitiveness if not reversed.
Inconsistent Revenue TrendsIrregular top-line performance hampers predictability for fixed-cost recovery and investment planning. For a capital-intensive CDMO, inconsistent volumes reduce capacity utilization and pricing leverage, pressuring gross margins and making multi-period planning for customer projects more difficult.
Volatile Free Cash FlowMaterial swings in free cash flow complicate capital allocation and raise the risk that future capex or working-capital needs will require external funding. Volatility reduces the reliability of cash available for debt repayment, dividends or strategic investments over the medium term.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹145.95 and its highest was ₹282.70 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹26.23B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Nov 18, 2026 which is in 91 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on Aug 06, 2026. The company reported -₹1.3 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.2 which represents an annual dividend yield of 0.46%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of -₹1.3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.221%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Dishman Carbogen Amcis Ltd.
―
Rossari Biotech Ltd
―
Solara Active Pharma Sciences Ltd.
―
Supriya Lifescience Limited
―
Wockhardt Limited
―